These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 11169767)

  • 1. Motor stimulant effects of the adenosine A(2A) receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats.
    Pinna A; Fenu S; Morelli M
    Synapse; 2001 Mar; 39(2):233-238. PubMed ID: 11169767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats.
    Pinna A; Fenu S; Morelli M
    Synapse; 2001 Mar; 39(3):233-8. PubMed ID: 11284438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic-intermittent L-dopa and A2A receptor blockade plus L-dopa in dopamine-denervated rats.
    Carta AR; Pinna A; Cauli O; Morelli M
    Synapse; 2002 Jun; 44(3):166-74. PubMed ID: 11954048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of A2A receptors plus l-DOPA after nigrostriatal lesion results in GAD67 mRNA changes different from l-DOPA alone in the rat globus pallidus and substantia nigra reticulata.
    Carta AR; Tabrizi MA; Baraldi PG; Pinna A; Pala P; Morelli M
    Exp Neurol; 2003 Dec; 184(2):679-87. PubMed ID: 14769359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adenosine A2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6-hydroxydopamine rat model of Parkinson's disease.
    Pinna A; Pontis S; Borsini F; Morelli M
    Synapse; 2007 Aug; 61(8):606-14. PubMed ID: 17476684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bilateral subthalamic nucleus lesion reverses L-dopa-induced motor fluctuations and facilitates dyskinetic movements in hemiparkinsonian rats.
    Marin C; Jiménez A; Tolosa E; Bonastre M; Bové J
    Synapse; 2004 Feb; 51(2):140-50. PubMed ID: 14618681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
    Agnati LF; Leo G; Vergoni AV; Martínez E; Hockemeyer J; Lluis C; Franco R; Fuxe K; Ferré S
    Brain Res Bull; 2004 Aug; 64(2):155-64. PubMed ID: 15342103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CSC counteracts l-DOPA-induced overactivity of the corticostriatal synaptic ultrastructure and function in 6-OHDA-lesioned rats.
    Huang YX; Luo WF; Li D; Hu WD; Liu CF
    Brain Res; 2011 Feb; 1376():113-21. PubMed ID: 21195062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenosine A2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats.
    Fenu S; Pinna A; Ongini E; Morelli M
    Eur J Pharmacol; 1997 Feb; 321(2):143-7. PubMed ID: 9063681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats.
    Tronci E; Simola N; Borsini F; Schintu N; Frau L; Carminati P; Morelli M
    Eur J Pharmacol; 2007 Jul; 566(1-3):94-102. PubMed ID: 17445798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease.
    Dekundy A; Pietraszek M; Schaefer D; Cenci MA; Danysz W
    Brain Res Bull; 2006 Apr; 69(3):318-26. PubMed ID: 16564428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned rats.
    Rose S; Ramsay Croft N; Jenner P
    Brain Res; 2007 Feb; 1133(1):110-4. PubMed ID: 17196564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets.
    Rose S; Jackson MJ; Smith LA; Stockwell K; Johnson L; Carminati P; Jenner P
    Eur J Pharmacol; 2006 Sep; 546(1-3):82-7. PubMed ID: 16925991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blockade of globus pallidus adenosine A(2A) receptors displays antiparkinsonian activity in 6-hydroxydopamine-lesioned rats treated with D(1) or D(2) dopamine receptor agonists.
    Simola N; Fenu S; Baraldi PG; Tabrizi MA; Morelli M
    Synapse; 2008 May; 62(5):345-51. PubMed ID: 18297692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SCH 58261, an A(2A) adenosine receptor antagonist, counteracts parkinsonian-like muscle rigidity in rats.
    Wardas J; Konieczny J; Lorenc-Koci E
    Synapse; 2001 Aug; 41(2):160-71. PubMed ID: 11400182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic effect of SCH 58261, an adenosine A2A receptor antagonist, and L-DOPA on the reserpine-induced muscle rigidity in rats.
    Wardas J
    Pol J Pharmacol; 2003; 55(2):155-64. PubMed ID: 12926542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of movement disorders and depression.
    Hodgson RA; Bertorelli R; Varty GB; Lachowicz JE; Forlani A; Fredduzzi S; Cohen-Williams ME; Higgins GA; Impagnatiello F; Nicolussi E; Parra LE; Foster C; Zhai Y; Neustadt BR; Stamford AW; Parker EM; Reggiani A; Hunter JC
    J Pharmacol Exp Ther; 2009 Jul; 330(1):294-303. PubMed ID: 19332567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-sensitization between caffeine- and L-dopa-induced behaviors in hemiparkinsonian mice.
    Yu L; Schwarzschild MA; Chen JF
    Neurosci Lett; 2006 Jan; 393(1):31-5. PubMed ID: 16236444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological characterization of a novel, potent adenosine A1 and A2A receptor dual antagonist, 5-[5-amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), in models of Parkinson's disease and cognition.
    Mihara T; Mihara K; Yarimizu J; Mitani Y; Matsuda R; Yamamoto H; Aoki S; Akahane A; Iwashita A; Matsuoka N
    J Pharmacol Exp Ther; 2007 Nov; 323(2):708-19. PubMed ID: 17684118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction between dopamine and adenosine A2A receptors as a basis for the treatment of Parkinson's disease.
    Morelli M; Pinna A
    Neurol Sci; 2001 Feb; 22(1):71-2. PubMed ID: 11487207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.